ImmuPharma plc (LON:IMM – Get Free Report) was down 15.6% on Wednesday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). Approximately 68,204,375 shares were traded during mid-day trading, an increase of 164% from the average daily volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Stock Down 15.6 %
The company has a market capitalization of £20.74 million, a P/E ratio of -498.00 and a beta of 1.53. The company’s 50-day moving average is GBX 1.98 and its two-hundred day moving average is GBX 1.80.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- 3 Small Caps With Big Return Potential
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Comparing and Trading High PE Ratio Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- What Does Downgrade Mean in Investing?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
